Patrick Ball, DO
Family Medicine · Southaven, MSNPI 1588743314
Payments from drug & device makers
Across 440 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- AbbVie$1K
- Novo Nordisk$960
- AstraZeneca$756
- Bayer$503
- Amgen$464
- plus $2K from 28 others
What the payments were for
- Food & beverage$7,082100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 96 | $1,245 |
| AbbVie(2 entities) | 56 | $1,013 |
| Novo Nordisk | 57 | $960 |
| AstraZeneca | 41 | $756 |
| Bayer | 24 | $503 |
| Amgen(2 entities) | 29 | $464 |
| Pfizer | 17 | $270 |
| Boehringer Ingelheim | 15 | $254 |
| GSK | 19 | $228 |
| Merck | 15 | $176 |
| Boston Scientific | 7 | $128 |
| Abbott | 6 | $115 |
| Johnson & Johnson | 8 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $103 |
| Daiichi Sankyo Inc. | 3 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $69 |
| Phathom Pharmaceuticals, Inc. | 5 | $67 |
| Dexcom, Inc. | 3 | $66 |
| Novartis | 2 | $55 |
| Kowa Pharmaceuticals America, Inc. | 4 | $54 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $39 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| Exact Sciences | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $30 |
| Shield Therapeutics Inc | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Genentech USA, Inc. | 2 | $27 |
| Pulmonx Corporation | 1 | $24 |
| Edwards Lifesciences | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$7,090 in reported general payments places this provider in the 90th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 250 | $272,702 |
| OzempicSemaglutide | 119 | $152,150 |
| JanuviaSitagliptin Phosphate | 115 | $107,767 |
| EliquisApixaban | 93 | $86,365 |
| TrulicityDulaglutide | 33 | $65,119 |
| FarxigaDapagliflozin Propanediol | 50 | $53,183 |
| MounjaroTirzepatide | 47 | $48,769 |
| XareltoRivaroxaban | 42 | $42,588 |
| RybelsusSemaglutide | 23 | $38,632 |
| MyrbetriqMirabegron | 45 | $34,347 |
| LinzessLinaclotide | 30 | $26,969 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 47 | $19,990 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $15,819 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $13,391 |
| Bydureon BciseExenatide Microspheres | 12 | $12,948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $254 | $272,702250 claims |
| Novo NordiskOzempic, Rybelsus | $960 | $190,781142 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,245 | $113,88880 claims |
| MerckJanuvia | $176 | $107,767115 claims |
| PfizerEliquis | $270 | $86,36593 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $756 | $64,99573 claims |
| Johnson & JohnsonXarelto | $113 | $42,58842 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $34,34745 claims |
| AbbVieLinzess, Synthroid | $1,013 | $30,02267 claims |
| GSKTrelegy Ellipta | $228 | $13,39113 claims |
| BayerKerendia | $503 | $12,43912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Southaven
- Walter CarnahanSouthaven$146K
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.